Re: Zenith Epigentics and Resverlogix update 22 Jan 2018

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigentics and Resverlogix update 22 Jan 2018

in response to

Zenith Epigentics and Resverlogix update 22 Jan 2018

tada

posted on Feb 01, 2018 11:38AM

Thanks for the post Tada! A great reminder of why we should all be excited about the potential of ZEN-3694 (and hopefully many other members of their compound library).